Latest News about JNJ
Recent news which mentions JNJ
Coinbase, Apple And Robinhood Are Among Top Large-Cap Losers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?
March 16, 2025
From Benzinga
Allegations of Inflated Prescription Drug Costs Spark Employee Lawsuit Against JPMorgan
March 15, 2025
From Benzinga
Kroger CEO Shake-Up
March 14, 2025
From Motley Fool
From Motley Fool
Generate Passive Income From This Low-Cost Vanguard ETF That Is Crushing the S&P 500 in 2025
March 14, 2025
From Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
March 11, 2025
From Benzinga
Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You?
March 11, 2025
From Motley Fool
How Exxon Mobil, Johnson & Johnson, And Cogent Communications Can Put Cash In Your Pocket
March 10, 2025
From Benzinga
From Motley Fool
From Benzinga
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
March 10, 2025
From Benzinga
From Benzinga
From Benzinga
2 Dow Stocks to Buy Hand Over Fist in March and 1 to Avoid
March 06, 2025
From Motley Fool
What 14 Analyst Ratings Have To Say About Johnson & Johnson
March 05, 2025
Tickers
JNJ
From Benzinga
Tech Sector Hammered As Trump's Tariff Plans Spark Market Selloff: Nvidia, ARM, Super Micro Lead Tech Bloodbath
March 04, 2025
From Benzinga
Warren Buffett's State of the Market
March 03, 2025
From Motley Fool
These Vanguard ETFs Show Where the Smart Money Is Moving Now
March 03, 2025
From Motley Fool
From Motley Fool
3 Dividend Stocks That Are No-Brainer Buys Right Now
March 01, 2025
From Motley Fool
Bitcoin, Magnificent 7 Lose Safe-Haven Status In 2025 As China ETFs, Dow Stocks Outperform
February 28, 2025
From Benzinga
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang
February 28, 2025
From Benzinga
Wall Street's Greatest Dividend Stock Just Made History Again -- and 99.9% of Investors Have Never Heard of This Small-Cap Company
February 28, 2025
From Motley Fool
Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says
February 27, 2025
From Benzinga
Johnson & Johnson Sues Samsung Bioepis Over Alleged Biosimilar Agreement Breach For Its Flagship Psoriasis Drug
February 26, 2025
From Benzinga
A Closer Look at Johnson & Johnson's Options Market Dynamics
February 26, 2025
Tickers
JNJ
From Benzinga
2 Very Healthy High-Yield Dividend Stocks to Buy for a Safe and Growing Passive Income Stream
February 24, 2025
From Motley Fool
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.